Clinical Trials · NCT07653477
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
- Enrollment
- 956
- Start date
- Jul 2026
- Locations
- See registry
- Primary endpoint
- HbA1c